Theriva Biologics reports positive Phase 1 data for VCN-01 in pediatric retinoblastoma and exclusive license from SJD

Theriva Biologics, Inc.

Phase 1 trial of intravitreal VCN-01 in 9 evaluable patients with refractory retinoblastoma determined positive by Monitoring Committee.
Safety: no dose-limiting toxicities; most adverse events Grade 1 or 2; no Grade 3+ ocular or systemic toxicities.
Antitumor activity: 4 patients had unequivocal improvement in vitreous seed density; eye enucleation avoided in 3 patients (1 retained eye after 4 years).
Theriva will receive exclusive worldwide license and related patents from Sant Joan de Déu-Barcelona Children's Hospital for advanced retinoblastoma treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.